Supersaturated dissolution data and their interpretation: The TPGS-carbamazepine model case

Journal of Pharmacy and Pharmacology

Volumn 63, Issue 3, 2011, Pages 352-361

  Charkoftaki, Georgia ^a   Dokoumetzidis, Aristides ^a   Valsami, Georgia ^a   Macheras, Panos ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Carbamazepine; Dissolution; Solubility; Supersaturation; Vitamin E TPGS

Indexed keywords

ALPHA TOCOPHEROL; ALPHA TOCOPHERYL POLYETHYLENE GLYCOL 1000 SUCCINATE; CARBAMAZEPINE; MACROGOL; MICROCRYSTALLINE CELLULOSE; SILICON DIOXIDE; UNCLASSIFIED DRUG;

ARTICLE; CONCENTRATION RESPONSE; DRUG EFFECT; DRUG SOLUBILITY; LIQUID; MAXIMUM PLASMA CONCENTRATION; REACTION TIME; SOLID; TEMPERATURE;

ANTICONVULSANTS; CARBAMAZEPINE; DRUG CARRIERS; MODELS, THEORETICAL; POLYETHYLENE GLYCOLS; SOLUBILITY; TEMPERATURE; VITAMIN E;

EID: 79952237126     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2010.01226.x     Document Type: Article

References (45)

1. Zhou H et al. Hydrophobic ion pairing of isoniazid using a prodrug approach. J Pharm 2002; 91: 1502-1511. (Pubitemid 34633965)
2. Vogt M et al. Dissolution improvement of four poorly water soluble drugs by cogrinding with commonly used excipients. Eur J Pharm Biopharm 2008; 68: 330-337.
3. Janssens S et al. Formulation and characterization of ternary solid dispersions made up of Itraconazole and two excipients, TPGS 1000 and PVPVA 64, that were selected based on a supersaturation screening study. Eur J Pharm Biopharm 2008; 69: 158-166.
4. Konno H et al. Effect of polymer type on the dissolution profile of amorphous solid dispersions containing felodipine. Eur J Pharm Biopharm 2008; 70: 493-499.
5. Shiraki K et al. Dissolution improvement and the mechanism of the improvement from cocrystallization of poorly water-soluble compounds. Pharm Res 2008; 25: 2581-2592.
6. Dhumal RS et al. Cefuroxime axetil solid dispersion with polyglycolized glycerides for improved stability and bioavailability. J Pharm Pharmacol 2009; 61: 743-751.
7. Sethia S, Squillante E. Physicochemical characterization of solid dispersions of carbamazepine formulated by supercritical carbon dioxide and conventional solvent evaporation methods. J Pharm Sci 2002; 91: 1948-1957. (Pubitemid 36254931)
8. Sethia S, Squillante E. Solid dispersion of carbamazepine in PVP K30 by conventional solvent evaporation and supercritical methods. Int J Pharm 2004; 272: 1-10. (Pubitemid 38293005)
9. Iervolino M et al. Membrane penetration enhancement of ibuprofen using supersaturation. Int J Pharm 2000; 198: 229-238. (Pubitemid 30184859)
10. Larrucea E et al. Study of the complexation behavior of tenoxicam with cyclodextrins in solution: improved solubility and percutaneous permeability. Drug Dev Ind Pharm 2002; 28: 245-252. (Pubitemid 34475671)
11. Gohel MC, Patel LD. Processing of nimesulide-PEG 400-PGPVP solid dispersions: preparation, characterization, and in vitro dissolution. Drug Dev Ind Pharm 2003; 29: 299-310. (Pubitemid 36528620)
12. Park SH, Choi HK. The effects of surfactants on the dissolution profiles of poorly water-soluble acidic drugs. Int J Pharm 2006; 321: 35-41.
13. Kalantzi L et al. Canine intestinal contents vs. simulated media for the assessment of solubility of two weak bases in the human small intestinal contents. Pharm Res 2006; 23: 1373-1381. (Pubitemid 43946159)
14. Brouwers J et al. In vitro behavior of a phosphate ester prodrug of amprenavir in human intestinal fluids and in the Caco-2 system: illustration of intraluminal supersaturation. Int J Pharm 2007; 336: 302-309. (Pubitemid 46670658)
15. Brouwers J et al. Parallel monitoring of plasma and intraluminal drug concentrations in man after oral administration of fosamprenavir in the fasted and fed state. Pharm Res 2007; 24: 1862-1869. (Pubitemid 47389240)
16. Clarysse S et al. Postprandial changes in solubilizing capacity of human intestinal fluids for BCS class II drugs. Pharm Res 2009; 26: 1456-1466.
17. Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm 2000; 50: 47-60. (Pubitemid 30326688)
18. Hancock B, Parks M. What is the true solubility advantage for amorphous pharmaceuticals? Pharm Res 2001; 17: 397-404. (Pubitemid 30395293)
19. Rogers TL et al. Development and characterization of a scalable controlled precipitation process to enhance the dissolution of poorly water-soluble drugs. Pharm Res 2004; 21: 2048-2057. (Pubitemid 40941225)
20. Raghavan SL et al. Effect of cellulose polymers on supersaturation and in vitro membrane transport of hydrocortisone acetate. Int J Pharm 2000; 193: 231-237. (Pubitemid 30001867)
21. Raghavan SL et al. Membrane transport of hydrocortisone acetate from supersaturated solutions; the role of polymers. Int J Pharm 2001; 221: 95-105. (Pubitemid 32524039)
22. Gunawan LG et al. Structural relaxation of acetaminophen glass. Pharm Res 2006; 23: 967-979.
23. Yamamoto K et al. Dissolution behavior and bioavailability of phenytoin from a ground mixture with microcrystalline cellulose. J Pharm Sci 1976; 65: 1484-1488.
24. Fujii M et al. Dissolution and bioavailability of phenobarbital in solid dispersion with phosphatidylcholine. Chem Pharm Bull 1991; 39: 1886-1888.
25. Suzki H, Sunada H. Influence of water-soluble polymers on the dissolution of nifedipine solid dispersions with combined carriers. Chem Pharm Bull 1998; 46: 482-487. (Pubitemid 28188567)
26. Urbanetz NA. Stabilization of solid dispersions of nimodipine and polyethylene glycol 2000. Eur J Pharm Sci 2006; 28: 67-76.
27. Valsami G et al. Modeling of supersaturated dissolution data. Int J Pharm 1999; 181: 153-157. (Pubitemid 29229802)
28. Kaneniwa N et al. Dissolution behaviour of carbamazepine polymorphs. Yakugaku Zasshi 1987; 107: 808-813. (Pubitemid 18084858)
29. Dokoumetzidis A et al. Development of a reaction-limited model of dissolution: Application to official dissolution tests experiments. Int J Pharm 2008; 355: 114-125.
30. Sugano K. A simulation of oral absorption using classical nucleation theory. Int J Pharm 2009; 378: 142-145.
31. Sugano K. Computational oral absorption simulation for low-solubility compounds. Chem Biodivers 2009; 6: 2014-2029.
32. Kobayashi Y et al. Physicochemical properties and bioavailability of carbamazepine polymorphs and dihydrate. Int J Pharm 2000; 193: 137-146. (Pubitemid 30001856)
33. Tian F et al. Influence of polymorphic form, morphology, and excipient interactions on the dissolution of carbamazepine compacts. J Pharm Sci 2007; 96: 584-594. (Pubitemid 46466080)
34. Sokol RJ et al. Improvement of cyclosporin absorption in children after liver transplantation by means of water-soluble vitamin E. Lancet 1991; 338: 212-214.
35. Ismailos G. In Vitro and in Vivo Studies on Cyclosporin Absorption Characteristics. Athens, Greece: National and Kapodistrian University of Athens, 1999. (dissertation).
36. Dokoumetzidis A, Macheras P. A century of dissolution research: From Noyes and Whitney to the Biopharmaceutics Classification System. Int J Pharm 2006; 321: 1-11. (Pubitemid 44247428)
37. Dejmek M, Ward CA. A statistical rate theory study of interface concentration during crystal growth or dissolution. J Chem Phys 1998; 108: 8698-8704. (Pubitemid 128597379)
38. Getsoian A et al. One-solvent polymorph screen of carbamazepine. Int J Pharm 2008; 348: 3-9. (Pubitemid 350266231)
39. Urakami K et al. A novel method for estimation of transition temperature for polymorphic pairs in pharmaceuticals using heat of solution and solubility data. Chem Pharm Bull (Tokyo) 2002; 50: 263-267. (Pubitemid 41694591)
40. Lehto P et al. Solvent-mediated solid phase transformations of carbamazepine: effects of simulated intestinal fluid and fasted state simulated intestinal fluid. J Pharm Sci 2009; 98: 985-996.
41. Sideris EE et al. Determination of association constants in cyclodextrin/drug complexation using the Scatchard plot: application to beta-cyclodextrin-anilinonaphthalenesulfonates. Pharm Res 1992; 9: 1568-1574.
42. Zografi G et al. Disperse systems. Surfactant properties in solutions and micelle formulation. Remington's Pharmaceutical Sciences, 18th edn. Easton, Pennsylvania: Mack Publishing Company, 18042, 1990: 257-309.
43. Kopelman R. Fractal reaction-kinetics. Science 1988; 241: 1620-1626.
44. Macheras P, Dokoumetzidis A. On the heterogeneity of drug dissolution and release. Pharm Res 2000; 17: 108-112. (Pubitemid 30158357)
45. Persson EM et al. The effects of food on the dissolution of poorly soluble drugs in human and in model small intestinal fluids. Pharm Res 2005; 22: 2141-2151. (Pubitemid 41821594)